---
document_datetime: 2025-12-02 05:17:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sotyktu.html
document_name: sotyktu.html
version: success
processing_time: 0.1054201
conversion_datetime: 2025-12-26 13:03:41.749508
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sotyktu

[RSS](/en/individual-human-medicine.xml/67656)

##### Authorised

This medicine is authorised for use in the European Union

deucravacitinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sotyktu](#news-on)
- [More information on Sotyktu](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Sotyktu is a medicine for treating adults with moderate to severe plaque psoriasis (an inflammatory disease causing red, scaly patches on the skin) who are eligible for systemic therapy (treatment with a medicine given by mouth or by injection).

Sotyktu contains the active substance deucravacitinib.

Expand section

Collapse section

## How is Sotyktu used?

Sotyktu can only be obtained with a prescription. Treatment should be started by a doctor experienced in the diagnosis and treatment of psoriasis.

Sotyktu is available as tablets, which the patient takes once a day. The doctor should evaluate the effect of the treatment regularly and may stop treatment if the condition does not improve after 24 weeks.

For more information about using Sotyktu, including dose recommendations, see the package leaflet or contact your doctor or pharmacist.

## How does Sotyktu work?

The active substance in Sotyktu, deucravacitinib, blocks the action of an enzyme inside cells called tyrosine kinase 2 (TYK2) which belongs to the Janus kinases (JAK) family of proteins. This enzyme plays a role in triggering the production of substances known as cytokines, which are involved in the inflammation and other processes that cause psoriasis. By blocking the action of TYK2, deucravacitinib prevents the production of cytokines, thereby reducing inflammation and improving the symptoms of plaque psoriasis.

## What benefits of Sotyktu have been shown in studies?

Two main studies involving 1,686 patients with moderate to severe plaque psoriasis compared Sotyktu with placebo (a dummy treatment) and apremilast, another systemic therapy for plaque psoriasis. The studies looked at an improvement of patients' symptoms after 16 weeks of treatment.

Around 55% of patients treated with Sotyktu had a reduction of at least 75% in their PASI score (a measure of the severity and extent of skin lesions) compared with around 38% of those treated with apremilast and around 11% of those who received placebo.

Additionally, around 51% of patients treated with Sotyktu achieved a sPGA score (a measure of the severity and extent of skin lesions) of 0 or 1 (where 0 and 1 refer to skin clear or almost clear, respectively) and had a reduction of 2 points or more in their sPGA score. Around 33% of those treated with apremilast and around 8% in those who received placebo had these results.

Improvement of symptoms were maintained after 52 weeks of treatment with Sotyktu.

## What are the risks associated with Sotyktu?

The most common side effect with Sotyktu (which may affect more than 1 in 10 people) is upper respiratory infection (nose and throat infection). For the full list of side effects of Sotyktu, see the package leaflet.

Patients who have an important or long-term infection, or an infection that keeps coming back, must not take this medicine. For the full list of restrictions, see the package leaflet.

## Why is Sotyktu authorised in the EU?

Studies show that Sotyktu is effective at reducing the symptoms of moderate to severe plaque psoriasis. Side effects are mild to moderate and manageable. Sotyktu provides an additional treatment option for patients who have not yet been treated with systemic therapy and those who do not benefit from other systemic therapies. Therefore, the European Medicines Agency decided that Sotyktu's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Sotyktu?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sotyktu have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sotyktu are continuously monitored. Suspected side effects reported with Sotyktu are carefully evaluated and any necessary action taken to protect patients.

## Other information about Sotyktu

Sotyktu received a marketing authorisation valid throughout the EU on 24 March 2023.

Sotyktu : EPAR - Medicine overview

Adopted

Reference Number: EMA/109564/2023

English (EN) (122.19 KB - PDF)

**First published:** 31/03/2023

[View](/en/documents/overview/sotyktu-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-161)

български (BG) (159.65 KB - PDF)

**First published:**

31/03/2023

[View](/bg/documents/overview/sotyktu-epar-medicine-overview_bg.pdf)

español (ES) (134.28 KB - PDF)

**First published:**

31/03/2023

[View](/es/documents/overview/sotyktu-epar-medicine-overview_es.pdf)

čeština (CS) (155.26 KB - PDF)

**First published:**

31/03/2023

[View](/cs/documents/overview/sotyktu-epar-medicine-overview_cs.pdf)

dansk (DA) (133.74 KB - PDF)

**First published:**

31/03/2023

[View](/da/documents/overview/sotyktu-epar-medicine-overview_da.pdf)

Deutsch (DE) (136.89 KB - PDF)

**First published:**

31/03/2023

[View](/de/documents/overview/sotyktu-epar-medicine-overview_de.pdf)

eesti keel (ET) (132.34 KB - PDF)

**First published:**

31/03/2023

[View](/et/documents/overview/sotyktu-epar-medicine-overview_et.pdf)

ελληνικά (EL) (159.73 KB - PDF)

**First published:**

31/03/2023

[View](/el/documents/overview/sotyktu-epar-medicine-overview_el.pdf)

français (FR) (135.07 KB - PDF)

**First published:**

31/03/2023

[View](/fr/documents/overview/sotyktu-epar-medicine-overview_fr.pdf)

hrvatski (HR) (156.32 KB - PDF)

**First published:**

31/03/2023

[View](/hr/documents/overview/sotyktu-epar-medicine-overview_hr.pdf)

italiano (IT) (133.65 KB - PDF)

**First published:**

31/03/2023

[View](/it/documents/overview/sotyktu-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (164.96 KB - PDF)

**First published:**

31/03/2023

[View](/lv/documents/overview/sotyktu-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (157.75 KB - PDF)

**First published:**

31/03/2023

[View](/lt/documents/overview/sotyktu-epar-medicine-overview_lt.pdf)

magyar (HU) (155.65 KB - PDF)

**First published:**

31/03/2023

[View](/hu/documents/overview/sotyktu-epar-medicine-overview_hu.pdf)

Malti (MT) (158.29 KB - PDF)

**First published:**

31/03/2023

[View](/mt/documents/overview/sotyktu-epar-medicine-overview_mt.pdf)

Nederlands (NL) (134.42 KB - PDF)

**First published:**

31/03/2023

[View](/nl/documents/overview/sotyktu-epar-medicine-overview_nl.pdf)

polski (PL) (157.3 KB - PDF)

**First published:**

31/03/2023

[View](/pl/documents/overview/sotyktu-epar-medicine-overview_pl.pdf)

português (PT) (134.86 KB - PDF)

**First published:**

31/03/2023

[View](/pt/documents/overview/sotyktu-epar-medicine-overview_pt.pdf)

română (RO) (156.18 KB - PDF)

**First published:**

31/03/2023

[View](/ro/documents/overview/sotyktu-epar-medicine-overview_ro.pdf)

slovenčina (SK) (156.18 KB - PDF)

**First published:**

31/03/2023

[View](/sk/documents/overview/sotyktu-epar-medicine-overview_sk.pdf)

slovenščina (SL) (155.42 KB - PDF)

**First published:**

31/03/2023

[View](/sl/documents/overview/sotyktu-epar-medicine-overview_sl.pdf)

Suomi (FI) (131.78 KB - PDF)

**First published:**

31/03/2023

[View](/fi/documents/overview/sotyktu-epar-medicine-overview_fi.pdf)

svenska (SV) (133.55 KB - PDF)

**First published:**

31/03/2023

[View](/sv/documents/overview/sotyktu-epar-medicine-overview_sv.pdf)

Sotyktu : EPAR - Risk Management Plan

English (EN) (4.9 MB - PDF)

**First published:** 31/03/2023

**Last updated:** 01/02/2024

[View](/en/documents/rmp/sotyktu-epar-risk-management-plan_en.pdf)

## Product information

Sotyktu : EPAR - Product information

English (EN) (414.94 KB - PDF)

**First published:** 31/03/2023

**Last updated:** 04/07/2024

[View](/en/documents/product-information/sotyktu-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-585)

български (BG) (380.57 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/bg/documents/product-information/sotyktu-epar-product-information_bg.pdf)

español (ES) (348.29 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/es/documents/product-information/sotyktu-epar-product-information_es.pdf)

čeština (CS) (358.57 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/cs/documents/product-information/sotyktu-epar-product-information_cs.pdf)

dansk (DA) (313 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/da/documents/product-information/sotyktu-epar-product-information_da.pdf)

Deutsch (DE) (330.06 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/de/documents/product-information/sotyktu-epar-product-information_de.pdf)

eesti keel (ET) (359.41 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/et/documents/product-information/sotyktu-epar-product-information_et.pdf)

ελληνικά (EL) (375.08 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/el/documents/product-information/sotyktu-epar-product-information_el.pdf)

français (FR) (371.48 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/fr/documents/product-information/sotyktu-epar-product-information_fr.pdf)

hrvatski (HR) (356.78 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/hr/documents/product-information/sotyktu-epar-product-information_hr.pdf)

íslenska (IS) (315.01 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/is/documents/product-information/sotyktu-epar-product-information_is.pdf)

italiano (IT) (371.41 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/it/documents/product-information/sotyktu-epar-product-information_it.pdf)

latviešu valoda (LV) (387.66 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/lv/documents/product-information/sotyktu-epar-product-information_lv.pdf)

lietuvių kalba (LT) (380.23 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/lt/documents/product-information/sotyktu-epar-product-information_lt.pdf)

magyar (HU) (379.3 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/hu/documents/product-information/sotyktu-epar-product-information_hu.pdf)

Malti (MT) (394.16 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/mt/documents/product-information/sotyktu-epar-product-information_mt.pdf)

Nederlands (NL) (366.36 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/nl/documents/product-information/sotyktu-epar-product-information_nl.pdf)

norsk (NO) (314.61 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/no/documents/product-information/sotyktu-epar-product-information_no.pdf)

polski (PL) (365.55 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/pl/documents/product-information/sotyktu-epar-product-information_pl.pdf)

português (PT) (315.8 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/pt/documents/product-information/sotyktu-epar-product-information_pt.pdf)

română (RO) (378.03 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/ro/documents/product-information/sotyktu-epar-product-information_ro.pdf)

slovenčina (SK) (391.17 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/sk/documents/product-information/sotyktu-epar-product-information_sk.pdf)

slovenščina (SL) (364.71 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/sl/documents/product-information/sotyktu-epar-product-information_sl.pdf)

Suomi (FI) (314.29 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/fi/documents/product-information/sotyktu-epar-product-information_fi.pdf)

svenska (SV) (313.18 KB - PDF)

**First published:**

31/03/2023

**Last updated:**

04/07/2024

[View](/sv/documents/product-information/sotyktu-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0011 03/07/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sotyktu : EPAR - All Authorised presentations

English (EN) (49.38 KB - PDF)

**First published:** 31/03/2023

[View](/en/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-881)

български (BG) (66.39 KB - PDF)

**First published:**

31/03/2023

[View](/bg/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_bg.pdf)

español (ES) (49.78 KB - PDF)

**First published:**

31/03/2023

[View](/es/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_es.pdf)

čeština (CS) (64.29 KB - PDF)

**First published:**

31/03/2023

[View](/cs/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (49.89 KB - PDF)

**First published:**

31/03/2023

[View](/da/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (50.13 KB - PDF)

**First published:**

31/03/2023

[View](/de/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (50.59 KB - PDF)

**First published:**

31/03/2023

[View](/et/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (66.72 KB - PDF)

**First published:**

31/03/2023

[View](/el/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_el.pdf)

français (FR) (49.64 KB - PDF)

**First published:**

31/03/2023

[View](/fr/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (56.22 KB - PDF)

**First published:**

31/03/2023

[View](/hr/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (50.36 KB - PDF)

**First published:**

31/03/2023

[View](/is/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_is.pdf)

italiano (IT) (49.75 KB - PDF)

**First published:**

31/03/2023

[View](/it/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (66.03 KB - PDF)

**First published:**

31/03/2023

[View](/lv/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (65.84 KB - PDF)

**First published:**

31/03/2023

[View](/lt/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (60.26 KB - PDF)

**First published:**

31/03/2023

[View](/hu/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (63.99 KB - PDF)

**First published:**

31/03/2023

[View](/mt/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (48.83 KB - PDF)

**First published:**

31/03/2023

[View](/nl/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (46.36 KB - PDF)

**First published:**

31/03/2023

[View](/no/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_no.pdf)

polski (PL) (57.74 KB - PDF)

**First published:**

31/03/2023

[View](/pl/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_pl.pdf)

português (PT) (50.38 KB - PDF)

**First published:**

31/03/2023

[View](/pt/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_pt.pdf)

română (RO) (84.35 KB - PDF)

**First published:**

31/03/2023

[View](/ro/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (58.07 KB - PDF)

**First published:**

31/03/2023

[View](/sk/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (53.28 KB - PDF)

**First published:**

31/03/2023

[View](/sl/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (45.73 KB - PDF)

**First published:**

31/03/2023

[View](/fi/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (49.45 KB - PDF)

**First published:**

31/03/2023

[View](/sv/documents/all-authorised-presentations/sotyktu-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sotyktu Active substance deucravacitinib International non-proprietary name (INN) or common name deucravacitinib Therapeutic area (MeSH) Psoriasis Anatomical therapeutic chemical (ATC) code L04AA

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Treatment of moderate-to-severe plaque psoriasis in adults.

## Authorisation details

EMA product number EMEA/H/C/005755

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Bristol-Myers Squibb Pharma EEIG

Plaza 254

Opinion adopted 26/01/2023 Marketing authorisation issued 24/03/2023 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sotyktu : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (110.84 KB - PDF)

**First published:** 21/12/2023

**Last updated:** 04/07/2024

[View](/en/documents/procedural-steps-after/sotyktu-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Sotyktu : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/68815/2023

English (EN) (10.61 MB - PDF)

**First published:** 31/03/2023

[View](/en/documents/assessment-report/sotyktu-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Sotyktu

Adopted

Reference Number: EMA/CHMP/898000/2023

English (EN) (129.72 KB - PDF)

**First published:** 27/01/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-sotyktu_en.pdf)

#### News on Sotyktu

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-january-2023) 27/01/2023

#### More information on Sotyktu

- [EMEA-002350-PIP01-18-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002350-pip01-18-m03)
- [EMEA-002350-PIP02-20-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002350-pip02-20-m01)
- [EMEA-002350-PIP05-23 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002350-pip05-23)
- [Long-term, observational cohort study of adults with plaque psoriasis (PsO), who are new users of deucravacitinib, tumour necrosis factor inhibitor (TNFi) biologics, non-TNFi biologics, or non-biologic therapies in the real-world clinical setting - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000659)

**This page was last updated on** 04/07/2024

## Share this page

[Back to top](#main-content)